- Conditions
- Brain and Central Nervous System Tumors, Cognitive/Functional Effects, Long-term Effects Secondary to Cancer Therapy in Adults, Long-term Effects Secondary to Cancer Therapy in Children, Poor Performance Status, Unspecified Adult Solid Tumor, Protocol Specific, Unspecified Childhood Solid Tumor, Protocol Specific
- Interventions
- irinotecan hydrochloride, cognitive assessment, management of therapy complications, radiation therapy
- Drug · Procedure · Radiation
- Lead sponsor
- University of California, Davis
- Other
- Eligibility
- 1 Year to 120 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2006
- U.S. locations
- 1
- States / cities
- Sacramento, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 409–432
of 5,025
matching trials from the live ClinicalTrials.gov search.
- Conditions
- MGMT-unmethylated Glioblastoma (GBM), GBM
- Interventions
- Nivolumab, Ipilimumab, Radiation Therapy (RT)
- Drug · Radiation
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Brain and Central Nervous System Tumors
- Interventions
- irinotecan hydrochloride, thalidomide
- Drug
- Lead sponsor
- Dartmouth-Hitchcock Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2008
- U.S. locations
- 2
- States / cities
- Lebanon, New Hampshire • Columbus, Ohio
- Conditions
- Cardiotoxicity, Heart Failure
- Interventions
- Not listed
- Lead sponsor
- Skribe Medical
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2027
- U.S. locations
- 11
- States / cities
- Golden, Colorado • Littleton, Colorado • Clearwater, Florida + 8 more
- Conditions
- Node-positive Breast Cancer
- Interventions
- Tailored axillary surgery - both Arms, Radiotherapy - Arm A, Radiotherapy - Arm B
- Procedure · Radiation
- Lead sponsor
- University Hospital, Basel, Switzerland
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2036
- U.S. locations
- 3
- States / cities
- Bethesda, Maryland • Durham, North Carolina • Seattle, Washington
- Conditions
- Radiation Cystitis, Urinary Tract Infection (Diagnosis)
- Interventions
- Hyperbaric Oxygen Therapy
- Other
- Lead sponsor
- Rachel A. Moses
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Lebanon, New Hampshire
- Conditions
- Head and Neck Carcinoma, Head and Neck Lymph Node, Head and Neck Squamous Cell Carcinoma, Laryngeal Neoplasm, Radiation Therapy Recipient
- Interventions
- Photoacoustic Imaging, Transcutaneous Acupoint Electrical Stimulation
- Procedure
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Triple Negative Breast Cancer, Hormone Receptor Positive (HR+), HER2-negative Breast Cancer, Biopsy-proven, Positive Lymph Node(s)
- Interventions
- Radiation Therapy Boost, Pembrolizumab, Paclitaxel, Carboplatin, Cyclophosphamide, Doxorubicin, Capecitabine
- Radiation · Drug
- Lead sponsor
- Laura M. Spring, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 10
- States / cities
- Washington D.C., District of Columbia • Baltimore, Maryland • Boston, Massachusetts + 6 more
- Conditions
- Pelvic Cancer
- Interventions
- Pelvic Exercise
- Behavioral
- Lead sponsor
- University of Massachusetts, Worcester
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Worcester, Massachusetts
- Conditions
- Brain and Central Nervous System Tumors
- Interventions
- dalteparin, radiation therapy
- Drug · Radiation
- Lead sponsor
- Eastern Cooperative Oncology Group
- Network
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2007
- U.S. locations
- 12
- States / cities
- Tampa, Florida • Urbana, Illinois • Kalamazoo, Michigan + 8 more
- Conditions
- Fibrosis
- Interventions
- Pentoxifylline, Vitamin E
- Drug
- Lead sponsor
- University of Iowa
- Other
- Eligibility
- 20 Years and older
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2012
- U.S. locations
- 1
- States / cities
- Iowa City, Iowa
- Conditions
- Salivary Gland Dysfunction, Xerostomia, Head and Neck Cancer
- Interventions
- Everolimus, Laboratory Biomarker Analysis, Survey Administration
- Drug · Other
- Lead sponsor
- University of Arizona
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Phoenix, Arizona
- Conditions
- Soft Tissue Sarcoma
- Interventions
- Sorafenib
- Drug
- Lead sponsor
- University of California, Davis
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 1
- States / cities
- Sacramento, California
- Conditions
- Malignant Solid Neoplasm, Hematopoietic and Lymphatic System Neoplasm
- Interventions
- Non-Interventional Study
- Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- Not listed
- Enrollment
- 200 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2027
- U.S. locations
- 7
- States / cities
- Scottsdale, Arizona • Jacksonville, Florida • Albert Lea, Minnesota + 4 more
- Conditions
- Cervical Cancer
- Interventions
- Discussion & scoring of health states related to the treatment of cervical cancer
- Other
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2013
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Head and Neck Cancer
- Interventions
- Bevacizumab, Erlotinib, Paclitaxel, 5-FU, Radiation Therapy
- Drug · Radiation
- Lead sponsor
- SCRI Development Innovations, LLC
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2012
- U.S. locations
- 7
- States / cities
- Fort Myers, Florida • Lakeland, Florida • Orlando, Florida + 4 more
- Conditions
- Locally Advanced Non-small Cell Lung Cancer
- Interventions
- vorinostat
- Drug
- Lead sponsor
- Fox Chase Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2019
- U.S. locations
- 3
- States / cities
- Tampa, Florida • Philadelphia, Pennsylvania • Charleston, South Carolina
- Conditions
- Pancreatic Neoplasms
- Interventions
- Avastin (Bevacizumab), Gemcitabine, Radiation Therapy
- Drug · Procedure
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Xerostomia
- Interventions
- Parotid sparing WBRT, Standard WBRT
- Radiation
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 3
- States / cities
- Ann Arbor, Michigan • Chapel Hill, North Carolina • Winston-Salem, North Carolina
- Conditions
- Sarcoma, Pediatric Brain Tumors
- Interventions
- Not listed
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 0 Years to 26 Years
- Enrollment
- 5,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2040
- U.S. locations
- 2
- States / cities
- Washington D.C., District of Columbia • Baltimore, Maryland
- Conditions
- Neoplasms
- Interventions
- Proton Therapy, Photon Therapy, SRS, Brachytherapy
- Radiation
- Lead sponsor
- Proton Collaborative Group
- Network
- Eligibility
- Not listed
- Enrollment
- 50,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2009
- U.S. locations
- 29
- States / cities
- Scottsdale, Arizona • Little Rock, Arkansas • San Diego, California + 25 more
- Conditions
- Breast Lesions, Breast Cyst, Early-Stage Breast Cancer, Benign Growth, Breast
- Interventions
- Not listed
- Lead sponsor
- Spectros Corporation
- Industry
- Eligibility
- 21 Years to 50 Years · Female only
- Enrollment
- 2,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2011
- U.S. locations
- 1
- States / cities
- Portola Valley, California
- Conditions
- Oropharyngeal p16INK4a-Negative Squamous Cell Carcinoma, Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage III Laryngeal Squamous Cell Carcinoma AJCC v6 and v7, Stage III Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IV Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage IV Laryngeal Squamous Cell Carcinoma AJCC v7, Stage IV Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage IV Oropharyngeal Squamous Cell Carcinoma AJCC v7
- Interventions
- Atezolizumab, Biopsy Procedure, Biospecimen Collection, Cetuximab, Cisplatin, Computed Tomography, Docetaxel, Intensity-Modulated Radiation Therapy, Magnetic Resonance Imaging, Survey Administration
- Drug · Procedure · Biological + 2 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 613 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2027
- U.S. locations
- 338
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 266 more
- Conditions
- Sarcoma
- Interventions
- filgrastim, dacarbazine, doxorubicin hydrochloride, ifosfamide, semaxanib, conventional surgery, radiation therapy
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- Radiation Therapy Oncology Group
- Network
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2003
- U.S. locations
- 207
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 163 more